Back to Search Start Over

Total body irradiation + fludarabine compared to busulfan + fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

Authors :
Giebel, Sebastian
Labopin, Myriam
Sobczyk-Kruszelnicka, Malgorzata
Stelljes, Matthias
Byrne, Jenny
Fegueux, Nathalie
Beelen, Dietrich
Rovira, Montserrat
Spyridonidis, Alexandros
Blaise, Didier
Bornhäuser, Martin
Karadogan, Ihsan
Savani, Bipin
Nagler, Arnon
Mohty, Mohamad
Martin, Sonja
Chevallier, Patrice
Neubauer, Andreas
Damaj, Gandhi
Koc, Yener
Ganser, Arnold
Collin, Matthew
Yakoub-Agha, Ibrahim
Ozdogu, Hakan
Araujo, Mercedes Colorado
Itäla-Remes, Maija
Orchard, Kim
Isaksson, Cecilia
Bethge, Wolfgang
Martin, Hans
Aljurf, Mahmoud
Faber, Edgar
Caballero, Dolores
Zák, Pavel
Leleu, Xavier
Bay, Jacques-Olivier
Rohrlich, Pierre-Simon
Kröger, Nicolaus
Huynh, Anne
Schäfer-Eckart, Kerstin
Milpied, Noel
Lenhoff, Stig
Ho, Aloysius
López, Jose Luis Bello
Mordini, Nicola
Lioure, Bruno
Halaburda, Kazimierz
Olivieri, Attilio
Gedde-Dahl, Tobias
Protheroe, Rachel
Tischer, Johanna
Klammer, Matthias
Clausen, Johannes
Potter, Victoria
Ladetto, Marco
Tilly, Herve
Deconinck, Eric
Brecht, Arne
Müller, Lutz Peter
Heinicke, Thomas
Carrete, Juan Pio Torres
Bazarbachi, Ali
Reményi, Péter
Rubio, Marie Thérèse
Fanin, Renato
Pérez-Simón, Jose Antonio
Niels, Murawski
Diez-Martin, J.
Arat, Mutlu
Hermine, Olivier
Socié, Gerard
Cornelissen, Jan
Santarone, Stella
Guyotat, Denis
Bulabois, Claude Eric
Bernasconi, Paolo
Johansson, Jan-Erik
Vrhovac, Radovan
Greinix, Hildegard
Lorenzo, José Luis López
Apte, Shashikant
Craddock, Charles
Kobbe, Guido
Zahrani, Mohsen Al
Dreger, Peter
Lange, Andrzej
Tbakhi, Abdelghani
Meijer, Ellen
Llamas, Carlos Vallejo
Santasusana, Josep Maria Ribera
Corradini, Paolo
Benedetti, Fabio
Rambaldi, Alessandro
Gandemer, Virginie
Malfuson, Jean-Valère
Kaare, Ain
Risitano, Antonio
Petrini, Mario
Selleri, Carmine
Wu, Depei
Hematology
CCA - Cancer Treatment and quality of life
Institut Paoli-Calmettes
Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)
Centre de Recherche en Cancérologie de Marseille (CRCM)
Aix Marseille Université (AMU)-Institut Paoli-Calmettes
Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Source :
Bone Marrow Transplantation, 56(2), 481-491. Nature Publishing Group, Giebel, S, Labopin, M, Sobczyk-Kruszelnicka, M, Stelljes, M, Byrne, J L, Fegueux, N, Beelen, D W, Rovira, M, Spyridonidis, A, Blaise, D, Bornhäuser, M, Karadogan, I, Savani, B N, Nagler, A, Mohty, M & Principal investigators of the contributing institutions 2021, ' Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT ', Bone Marrow Transplantation, vol. 56, no. 2, pp. 481-491 . https://doi.org/10.1038/s41409-020-01050-7, Bone Marrow Transplantation, Bone Marrow Transplantation, 2021, 56 (2), pp.481-491. ⟨10.1038/s41409-020-01050-7⟩
Publication Year :
2021

Abstract

International audience; The optimal conditioning for patients with acute myeloid leukemia in first complete remission treated with allogeneic hematopoietic cell transplantation (allo-HCT) has not been defined so far. In this retrospective study, we compared two "reduced-toxicity" regimens: intravenous busulfan at a total dose of 9.6 mg/kg (3 days) + fludarabine (Bu3/Flu) and total body irradiation at a dose of 8 Gy + fludarabine (TBI8Gy/Flu). In the entire study cohort (n = 518), the probabilities of overall survival (OS), leukemia-free survival (LFS), relapse and non-relapse mortality (NRM) at 2 years for Bu3/Flu and TBI8Gy/Flu were 62% vs. 72.5% (p = 0.051), 59.5% vs. 65% (p = 0.15), 30% vs. 20% (p = 0.01), and 10% vs. 14% (p = 0.18), respectively. In multivariate model for patients

Details

Language :
English
ISSN :
02683369
Volume :
56
Issue :
2
Database :
OpenAIRE
Journal :
Bone Marrow Transplantation
Accession number :
edsair.doi.dedup.....7a271bda3480115a5c698ba5b59f0ad1